SCHEDULE: Wellington Management Boosts Apellis Stake to 7.17%

Wellington Management Group and its affiliates have reported a 7.17% beneficial ownership stake in Apellis Pharmaceuticals, Inc. as of June 30, 2025.

Summary

• Wellington Management Group LLP, along with its affiliates Wellington Group Holdings LLP, Wellington Investment Advisors Holdings LLP, and Wellington Management Company LLP, collectively hold a beneficial ownership of 9,009,522 shares of Apellis Pharmaceuticals, Inc. Common Stock.
• This aggregate ownership represents 7.17% of the class of securities.
• The reporting entities have shared voting power over 8,713,716 shares and shared dispositive power over 9,009,522 shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Apellis Pharmaceuticals, Inc.

Sentiment

Score: 5

Explanation: This is a factual disclosure of beneficial ownership, indicating a neutral sentiment. It does not contain performance data or forward-looking statements that would influence sentiment.

Future Outlook

NA

Industry Context

This filing indicates a significant passive investment by a major asset manager, Wellington Management, in Apellis Pharmaceuticals, a biotechnology company. Such institutional holdings are common in the pharmaceutical and biotech sectors, reflecting investor confidence or strategic positioning within the industry.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's stake, which can influence market perception and liquidity.
• Company Management: Awareness of a large, passive institutional investor on the shareholder register.

Key Dates

Keywords

Apellis Pharmaceuticals, Wellington Management, Beneficial Ownership, Institutional Investor, Common Stock, Healthcare, Biotechnology, Investment Management, SEC Filing, Schedule 13G